Adimmune (TPE:4142) Cyclically Adjusted Revenue per Share: NT$4.35 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4142 Adimmune Corp TPE:4142
50 GF Score
Price NT$16.80
GF Value NT$25.76
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Adimmune Cyclically Adjusted Revenue per Share?

Adimmune TPE:4142 -3.17% 50 Cyclically Adjusted Revenue per Share is NT$4.35 as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 50/100 and a GF Value™ of NT$25.76 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Adimmune's adjusted revenue per share for the three months ended in Dec. 2025 was NT$1.769. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$4.35 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Adimmune's average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Adimmune was 12.20% per year. The lowest was 6.20% per year. And the median was 8.90% per year.

As of today (2026-07-18), Adimmune's current stock price is NT$16.80. Adimmune's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$4.35. Adimmune's Cyclically Adjusted PS Ratio of today is 3.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Adimmune was 31.38. The lowest was 3.86. And the median was 9.67.


Adimmune  (TPE:4142) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Adimmune's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.80/4.35
=3.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Adimmune was 31.38. The lowest was 3.86. And the median was 9.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Adimmune Cyclically Adjusted Revenue per Share Related Terms


Adimmune Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Adimmune's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adimmune Cyclically Adjusted Revenue per Share Chart

Adimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.16 3.63 3.90 4.08 4.35

Adimmune Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.08 4.14 4.18 4.26 4.35

TPE:4142 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Adimmune's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adimmune Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adimmune's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Adimmune's Cyclically Adjusted PS Ratio falls into.


TPE:4142
50GF Score
Adimmune Corp TPE:4142
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adimmune Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adimmune's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=1.769/324.0540*324.0540
=1.769

Current CPI (Dec. 2025) = 324.0540.

Adimmune Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.183 238.132 0.249
201606 0.453 241.018 0.609
201609 0.623 241.428 0.836
201612 1.201 241.432 1.612
201703 0.305 243.801 0.405
201706 0.201 244.955 0.266
201709 0.920 246.819 1.208
201712 0.853 246.524 1.121
201803 0.284 249.554 0.369
201806 0.131 251.989 0.168
201809 1.570 252.439 2.015
201812 1.626 251.233 2.097
201903 0.254 254.202 0.324
201906 0.379 256.143 0.479
201909 1.421 256.759 1.793
201912 1.729 256.974 2.180
202003 0.988 258.115 1.240
202006 0.155 257.797 0.195
202009 1.464 260.280 1.823
202012 1.894 260.474 2.356
202103 0.016 264.877 0.020
202106 0.205 271.696 0.245
202109 1.732 274.310 2.046
202112 2.199 278.802 2.556
202203 0.123 287.504 0.139
202206 1.280 296.311 1.400
202209 2.540 296.808 2.773
202212 1.376 296.797 1.502
202303 0.403 301.836 0.433
202306 0.195 305.109 0.207
202309 2.325 307.789 2.448
202312 1.327 306.746 1.402
202403 0.104 312.332 0.108
202406 0.189 314.175 0.195
202409 2.092 315.301 2.150
202412 1.293 315.605 1.328
202503 0.171 319.799 0.173
202506 0.258 322.561 0.259
202509 1.041 324.800 1.039
202512 1.769 324.054 1.769

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$4.35 mean?
Adimmune (TPE:4142) has a Cyclically Adjusted Revenue per Share of NT$4.35 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Adimmune and its competitors.
Is Adimmune's Cyclically Adjusted Revenue per Share too high?
Adimmune's current Cyclically Adjusted Revenue per Share is NT$4.35. Overall, Adimmune has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Adimmune's Cyclically Adjusted Revenue per Share of NT$4.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Adimmune and its competitors. Adimmune's current Cyclically Adjusted Revenue per Share is NT$4.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.76, compared to a current price of NT$16.80 — trading 34.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$4.35. Adimmune's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Cyclically Adjusted Revenue per Share is NT$4.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$16.80 is trading 34.8% below its estimated GF Value™ of NT$25.76. GuruFocus considers Adimmune to be Possible Value Trap.

Key valuation signals for TPE:4142:

  • Cyclically Adjusted Revenue per Share: NT$4.35
  • GF Value™: NT$25.76 vs. price of NT$16.80 (34.8% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
50GF Score

Get the complete analysis for TPE:4142

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.80
Price
NT$25.76
GF Value